SARS-CoV-2 antibodies detected in blood donor samples indicate infections could have occurred in the US more than a month before the first confirmed case, but some experts remain skeptical.

Fewer than 1 in 10 dialysis patients sampled had antibodies against the novel coronavirus as of July, indicating that the greater population is far from levels required to achieve herd immunity.

The results from a study in Iceland can’t say if a recovered patient’s antibodies can protect them from subsequent reinfection.

Actual cases may be as much as 6 to 24 times higher than reported, but we’re still a long way off from herd immunity.

After initial setbacks, the country’s recent antibody screen estimates that 5 percent of the population has been exposed to SARS-CoV-2.

The FDA cracks down on test makers as independent evaluations of their products’ performance show a need for improvement.